Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 微生物學科所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78581
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor葉秀慧(Shiou-Hwei Yeh)
dc.contributor.authorChun-Ying Huangen
dc.contributor.author黃俊穎zh_TW
dc.date.accessioned2021-07-11T15:05:20Z-
dc.date.available2024-08-29
dc.date.copyright2019-08-29
dc.date.issued2019
dc.date.submitted2019-08-14
dc.identifier.citation1. Mak LY, Wong DK, Seto WK, Lai CL, Yuen MF. Hepatitis B core protein as a therapeutic target. Expert Opin Ther Targets. 2017 Dec;21(12):1153-9.
2. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016 Apr;64(1 Suppl):S4-S16.
3. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014 Jan;98(1):39-54.
4. Garcia PD, Ou JH, Rutter WJ, Walter P. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J Cell Biol. 1988 Apr;106(4):1093-104.
5. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015 May;479-480:672-86.
6. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011 Nov;55(5):996-1003.
7. Somiya M, Liu Q, Yoshimoto N, Iijima M, Tatematsu K, Nakai T, et al. Cellular uptake of hepatitis B virus envelope L particles is independent of sodium taurocholate cotransporting polypeptide, but dependent on heparan sulfate proteoglycan. Virology. 2016 Oct;497:23-32.
8. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;1:e00049.
9. Gallucci L, Kann M. Nuclear Import of Hepatitis B Virus Capsids and Genome. Viruses. 2017 Jan 21;9(1).
10. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015 Dec;64(12):1972-84.
11. Hu J, Lin L. RNA-protein interactions in hepadnavirus reverse transcription. Front Biosci (Landmark Ed). 2009 Jan 1;14:1606-18.
12. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol. 1994 Jan;68(1):6-13.
13. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008 Jun;134(1-2):235-49.
14. Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017 Mar 21;9(3).
15. Blumberg BS. Australia antigen and the biology of hepatitis B. Science. 1977 Jul 1;197(4298):17-25.
16. Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. Front Microbiol. 2018;9:662.
17. Ning X, Nguyen D, Mentzer L, Adams C, Lee H, Ashley R, et al. Secretion of genome-free hepatitis B virus--single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog. 2011 Sep;7(9):e1002255.
18. Luckenbaugh L, Kitrinos KM, Delaney WEt, Hu J. Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy. J Viral Hepat. 2015 Jun;22(6):561-70.
19. Steven AC, Conway JF, Cheng N, Watts NR, Belnap DM, Harris A, et al. Structure, assembly, and antigenicity of hepatitis B virus capsid proteins. Adv Virus Res. 2005;64:125-64.
20. Hatton T, Zhou S, Standring DN. RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J Virol. 1992 Sep;66(9):5232-41.
21. Li HC, Huang EY, Su PY, Wu SY, Yang CC, Lin YS, et al. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog. 2010 Oct 28;6(10):e1001162.
22. Birnbaum F, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol. 1990 Jul;64(7):3319-30.
23. Suzuki T, Masui N, Kajino K, Saito I, Miyamura T. Detection and mapping of spliced RNA from a human hepatoma cell line transfected with the hepatitis B virus genome. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8422-6.
24. Ito N, Nakashima K, Sun S, Ito M, Suzuki T. Cell Type Diversity in Hepatitis B Virus RNA Splicing and Its Regulation. Front Microbiol. 2019;10:207.
25. Chen J, Wu M, Wang F, Zhang W, Wang W, Zhang X, et al. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Sci Rep. 2015 Nov 20;5:16459.
26. Soussan P, Pol J, Garreau F, Schneider V, Le Pendeven C, Nalpas B, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis. 2008 Jul 15;198(2):218-25.
27. Wu HL, Chen PJ, Tu SJ, Lin MH, Lai MY, Chen DS. Characterization and genetic analysis of alternatively spliced transcripts of hepatitis B virus in infected human liver tissues and transfected HepG2 cells. J Virol. 1991 Apr;65(4):1680-6.
28. Roossinck MJ, Siddiqui A. In vivo phosphorylation and protein analysis of hepatitis B virus core antigen. J Virol. 1987 Apr;61(4):955-61.
29. Liao W, Ou JH. Phosphorylation and nuclear localization of the hepatitis B virus core protein: significance of serine in the three repeated SPRRR motifs. J Virol. 1995 Feb;69(2):1025-9.
30. Zhao Q, Hu Z, Cheng J, Wu S, Luo Y, Chang J, et al. Hepatitis B Virus Core Protein Dephosphorylation Occurs during Pregenomic RNA Encapsidation. J Virol. 2018 Jul 1;92(13).
31. Kock J, Kann M, Putz G, Blum HE, Von Weizsacker F. Central role of a serine phosphorylation site within duck hepatitis B virus core protein for capsid trafficking and genome release. J Biol Chem. 2003 Jul 25;278(30):28123-9.
32. Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. Core protein: A pleiotropic keystone in the HBV lifecycle. Antiviral Res. 2015 Sep;121:82-93.
33. Ludgate L, Liu K, Luckenbaugh L, Streck N, Eng S, Voitenleitner C, et al. Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation. J Virol. 2016 Jun 15;90(12):5830-44.
34. Chen C, Wang JC, Zlotnick A. A kinase chaperones hepatitis B virus capsid assembly and captures capsid dynamics in vitro. PLoS Pathog. 2011 Nov;7(11):e1002388.
35. Albin C, Robinson WS. Protein kinase activity in hepatitis B virus. J Virol. 1980 Apr;34(1):297-302.
36. Lanford RE, Luckow V, Kennedy RC, Dreesman GR, Notvall L, Summers MD. Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J Virol. 1989 Apr;63(4):1549-57.
37. Kann M, Gerlich WH. Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus. J Virol. 1994 Dec;68(12):7993-8000.
38. Duclos-Vallee JC, Capel F, Mabit H, Petit MA. Phosphorylation of the hepatitis B virus core protein by glyceraldehyde-3-phosphate dehydrogenase protein kinase activity. J Gen Virol. 1998 Jul;79 ( Pt 7):1665-70.
39. Kau JH, Ting LP. Phosphorylation of the core protein of hepatitis B virus by a 46-kilodalton serine kinase. J Virol. 1998 May;72(5):3796-803.
40. Daub H, Blencke S, Habenberger P, Kurtenbach A, Dennenmoser J, Wissing J, et al. Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J Virol. 2002 Aug;76(16):8124-37.
41. Ludgate L, Ning X, Nguyen DH, Adams C, Mentzer L, Hu J. Cyclin-dependent kinase 2 phosphorylates s/t-p sites in the hepadnavirus core protein C-terminal domain and is incorporated into viral capsids. J Virol. 2012 Nov;86(22):12237-50.
42. Diab A, Foca A, Fusil F, Lahlali T, Jalaguier P, Amirache F, et al. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication. Hepatology. 2017 Dec;66(6):1750-65.
43. Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017 Apr 20;169(3):381-405.
44. Fayard E, Tintignac LA, Baudry A, Hemmings BA. Protein kinase B/Akt at a glance. J Cell Sci. 2005 Dec 15;118(Pt 24):5675-8.
45. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011 Oct;23(10):1515-27.
46. Siess KM, Leonard TA. Lipid-dependent Akt-ivity: where, when, and how. Biochem Soc Trans. 2019 Jun 28;47(3):897-908.
47. Tuncel G, Kalkan R. Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme. Med Oncol. 2018 Aug 4;35(9):122.
48. Ebner M, Lucic I, Leonard TA, Yudushkin I. PI(3,4,5)P3 Engagement Restricts Akt Activity to Cellular Membranes. Mol Cell. 2017 Feb 2;65(3):416-31 e6.
49. Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer. 2010 Dec;1(12):1170-7.
50. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008 Jan 25;283(4):1882-92.
51. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005 Apr 1;18(1):13-24.
52. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007 Jan;45(1):42-52.
53. Cheng D, Zhang L, Yang G, Zhao L, Peng F, Tian Y, et al. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int. 2015 Jun;35(6):1682-91.
54. Cooray S. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol. 2004 May;85(Pt 5):1065-76.
55. Guo H, Zhou T, Jiang D, Cuconati A, Xiao GH, Block TM, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol. 2007 Sep;81(18):10072-80.
56. Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol. 2015 Jan 15;89(2):999-1012.
57. Lamontagne J, Mell JC, Bouchard MJ. Transcriptome-Wide Analysis of Hepatitis B Virus-Mediated Changes to Normal Hepatocyte Gene Expression. PLoS Pathog. 2016 Feb;12(2):e1005438.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78581-
dc.description.abstract構成B型肝炎病毒(Hepatitis B virus, HBV)核殼(nucleocapsid)的核殼蛋白 (HBV core protein, HBc)為一磷酸化蛋白質,其C端的S155、S162、S170為三個最主要的磷酸化位點。近年研究顯示核殼蛋白的磷酸化狀態在HBV生活史中呈現動態變化,亦即核殼蛋白在進行pgRNA encapsidation前呈現高度磷酸化,但在進行pgRNA encapsidation以及後續包膜(envelopement)及分泌(secretion)至細胞外的複製過程中皆呈現去磷酸化狀態,意味著核殼蛋白的磷酸化與去磷酸化修飾在HBV生活史中扮演重要功能。然而,負責調控核殼蛋白磷酸化修飾的激酶(kinase),和激酶所調控的特定磷酸化位點之功能仍不清楚。
本研究著眼於S170位點,首先利用基因體點突變的方式,將S170改變為Alanine及Aspartate,發現S170位點的磷酸化決定核殼蛋白是否能包裹pgRNA和合成DNA。接著利用回補的方式分別探討HBc及由SP1 splicing RNA所轉錄缺少C端最後一個胺基酸Cysteine之HBc-Cys蛋白中S170的功能,發現HBc及HBc-Cys蛋白對於DNA合成以及核殼組裝有不同的影響。為了驗證基因體點突變研究策略的結果,在不改變核殼蛋白胺基酸序列的情況下探討S170位點磷酸化的功能,我們嘗試尋找負責S170磷酸化之激酶及抑制劑。藉助於本實驗室所製備可專一性辨識去磷酸化S170之抗體,進行kinase inhibitor library之篩選,發現候選激酶Akt抑制劑的處理,會降低核殼蛋白的170位點磷酸化程度,進一步發現在Akt抑制劑處理下,HBV replicon所表現的disulfide bond-linkage HBc dimers和capsids及capsid所包裹的DNA皆顯著減少。以上結果表示Akt很可能是調控核殼蛋白磷酸化之激酶,目前正利用in vitro kinase assay來驗證此可能性,並進行確認特定Akt isoform,包括Akt1、Akt2及Akt3對HBc及HBc-Cys蛋白之磷酸化及其對調控HBV之複製過程,包括dimer/capsid之形成及pgRNA encapsidation之具體作用。
zh_TW
dc.description.abstractHBV core protein (HBc), the main structural protein of HBV icosahedral nucleocapsid, is a phosphoprotein. It contains three major conserved serine phosphorylation sites at S155, S162, and S170 in C-terminal domain. Recently, it was demonstrated that HBc undergoes dynamic phosphorylation during viral replication. HBc is highly phosphorylated before RNA encapsidation, which is dephosphorylated afterwards until envelopment and virion secretion. Therefore, HBc phosphorylation and dephosphorylation might play important role in viral replication. However, the putative kinase for specific Ser residue and the exact function still remains unclear.
To focus on S170, we first took the genetic approach to generate the HBV replicons with S170A and S170D mutations. S170A but not S170D is unable to synthesize the capsid associated DNA, supporting the critical role of S170 phosphorylation in viral replicaion. Furthermore, we took complementation approach to analyze the individual function of S170 phosphorylation in HBc and SP1 splicing RNA encoded HBc-Cys, the two components in viral capsids, in viral replication. The results showed different function HBc and HBc-Cys in capsid assembly and DNA synthesis. Next, we have tried to identify the putative kinase and also the specific kinase inhibitor for S170, which might help study the function of S170 phosphorylation in the wild type HBc and HBc-Cys containing viral replicons. Aided by CS-170 Ab, which specifically recognizes the dephospho-S170 HBc, we screened a kinase inhibitor library and found that S170 the phosphorylation was decreased by a putative Akt inhibitor. The Akt inhibitor treatment decreased the expression of capsid protein, the capsid formation and also the capsid-associated DNA, suggesting the critical role of S170 phsophoayrlion in capsid assembly and DNA synthesis. The identity of Akt as the putative kinase for S170 is currently under investigation, approached by the in vitro kinase assay and si-RNA studuies. Moreover, the effect of specific isoform of Akt, including Akt1-3, on HBc and HBc-Cys in capsid assembly and DNA synthesis is also under invstigation. We expect the results can help clarify the kinase and the function of specific HBc-S170 phosphorylation in viral replication cycle.
en
dc.description.provenanceMade available in DSpace on 2021-07-11T15:05:20Z (GMT). No. of bitstreams: 1
ntu-108-R06445102-1.pdf: 1961772 bytes, checksum: dae4ddc2810c8801d2cf376f995b49c2 (MD5)
Previous issue date: 2019
en
dc.description.tableofcontents碩士論文口試委員審定書 i
誌謝 ii
摘要 iii
Abstract iv
目錄 - 1 -
圖表目錄 - 3 -
第一章 序論 - 4 -
1.1 B型肝炎病毒(HBV)簡介 Hepatitis B virus (HBV) - 4 -
1.2 HBV的基因體結構 Genome structure and organization of HBV - 4 -
1.3 HBV生活史 HBV life cycle - 5 -
1.4完全病毒顆粒與不完全病毒顆粒 Complete and incomplete HBV particles - 6 -
1.5 HBV核殼蛋白之結構 The structure of HBV core protein (HBc) - 7 -
1.6 HBV 剪接RNA SP1及其轉譯之蛋白質HBV SP1 and the SP1-encoded protein HBc-Cys - 7 -
核殼蛋白的磷酸化位點在HBV複製過程中所扮演的角色 Roles of three major HBc-CTD phosphorylation sites in the life cycle of HBV - 9 -
可能參與調控核殼蛋白磷酸化的激酶 Putative kinases for HBc-CTD phosphorylation sites - 10 -
Akt/PKB (Protein kinase B) - 11 -
第二章 實驗材料與方法 - 14 -
3.1 質體建構 (Plasmids) - 14 -
3.2 細胞培養 (Cell culture) - 15 -
3.3 細胞轉染 (Transfection) - 16 -
3.4 蛋白質抽取 (Protein extraction) - 16 -
3.5 去磷酸化反應 (Lambda Protein Phosphatase reaction) - 16 -
3.6 西方墨點法 (Western blot) - 17 -
3.7 HBV capsid 之偵測 (Native Agarose gel electrophoresis) - 17 -
3.8 HBV capsid-associated DNA之偵測 (Particle-gel assay) - 17 -
3.9 蔗糖溶液梯度離心 (Sucrose gradient centrifugation) - 18 -
3.10 抗體 (Antibodies) - 18 -
第三章 結果 - 20 -
3.1 HBc S170位點的磷酸化決定核殼蛋白是否能包裹pgRNA和合成DNA - 20 -
3.2 HBc和HBc-Cys蛋白及其S170位點之磷酸化修飾各自有其對核殼組裝及DNA合成之影響 - 21 -
3.3 HBc 和HBc-Cys 之S170磷酸化位點皆參與各自的核殼組裝 - 23 -
3.4 HBc-S170A無法進行有效且正確之Capsid組裝 - 24 -
3.5 Akt抑制劑能降低HBc S170位點磷酸化程度,且呈現dose-dependent effect - 25 -
3.6 Akt抑制劑降低HBc S170位點磷酸化程度,促使核殼組裝量增加,且此現象能被過度表現之myr-Akt3所抵銷 - 27 -
3.7 Akt抑制劑促使HBc-Cys核殼組裝量增加,且此現象能被過度表現之myr-Akt3所抵銷 - 28 -
3.8 Akt抑制劑顯著減少HBV replicon系統中disulfide bond-linkage HBc dimers、capsids及capsid所包裹的DNA表現量 - 28 -
第四章 討論 - 30 -
參考文獻 - 32 -
dc.language.isozh-TW
dc.subjectB型肝炎病毒zh_TW
dc.subject核殼蛋白zh_TW
dc.subject磷酸激?zh_TW
dc.subject核殼組裝zh_TW
dc.subject磷酸化zh_TW
dc.subjectnucleocapsiden
dc.subjecthepatitis B virusen
dc.subjectphosphorylationen
dc.subjectcapsid assemblyen
dc.subjectkinaseen
dc.title探討B型肝炎病毒核殼蛋白Serine 170位點磷酸化修飾之激酶及其對病毒複製之影響zh_TW
dc.titleInvestigate the Putative Kinase and Function for the Phosphorylation of HBV Capsid Protein at Serine-170en
dc.typeThesis
dc.date.schoolyear107-2
dc.description.degree碩士
dc.contributor.oralexamcommittee陳培哲(Pei-Jer Chen),鄧述諄(Shu-Chun Teng),王聖涵(Sheng-Han Wang)
dc.subject.keywordB型肝炎病毒,核殼蛋白,磷酸化,核殼組裝,磷酸激?,zh_TW
dc.subject.keywordhepatitis B virus,nucleocapsid,phosphorylation,capsid assembly,kinase,en
dc.relation.page45
dc.identifier.doi10.6342/NTU201903733
dc.rights.note有償授權
dc.date.accepted2019-08-15
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept微生物學研究所zh_TW
dc.date.embargo-lift2024-08-29-
顯示於系所單位:微生物學科所

文件中的檔案:
檔案 大小格式 
ntu-108-R06445102-1.pdf
  未授權公開取用
1.92 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved